NME6 Antibody / Nucleoside Diphosphate Kinase 6 Antibody (RQ8417)

NME6 Antibody Human HeLa Cervical Cancer Cell IF/ICC. Immunofluorescent staining of human HeLa cervical cancer cells was performed with NME6 Antibody at 5 ug/ml following enzyme antigen retrieval. Cy3-conjugated secondary antibody was used to visualize NME6 (red), with DAPI as a nuclear counterstain (blue). NME6 staining shows a predominantly cytoplasmic, punctate distribution surrounding the nuclei, consistent with mitochondrial localization. This NME6 Antibody demonstrates cellular localization of Nucleoside Diphosphate Kinase 6 in human HeLa cervical cancer cells.

NME6 Antibody Human Cancer Cell WB. Western blot analysis was performed with NME6 Antibody on human LNCaP prostate cancer, U2OS osteosarcoma, Caco-2 colorectal cancer and A431 epidermoid carcinoma cell lysates (lanes 1-4). Samples were separated by 5-20% SDS-PAGE under reducing conditions, and the antibody was used at 0.5 ug/ml overnight at 4oC. A specific band is detected at approximately 21 kDa, consistent with the expected molecular weight of NME6. This NME6 Antibody demonstrates detection of Nucleoside Diphosphate Kinase 6 across multiple human cancer cell lines.

NME6 Antibody Human Colon Cancer IHC. IHC staining of FFPE human colon cancer tissue was performed with NME6 Antibody at 2 ug/ml following heat-induced epitope retrieval in pH 8 EDTA buffer. HRP-conjugated secondary antibody and DAB were used for detection. NME6 staining is observed predominantly in the cytoplasm of tumor cells, with variable staining intensity across the tissue. This NME6 Antibody demonstrates localization of Nucleoside Diphosphate Kinase 6 in human colon cancer tissue.

NME6 Antibody Human Placenta IHC. IHC staining of FFPE human placenta tissue was performed with NME6 Antibody at 2 ug/ml following heat-induced epitope retrieval in pH 8 EDTA buffer. HRP-conjugated secondary antibody and DAB were used for detection. NME6 staining is observed in placental villi, with predominantly cytoplasmic staining in trophoblast cells. This NME6 Antibody demonstrates localization of Nucleoside Diphosphate Kinase 6 in human placenta tissue.

NME6 Antibody Human Lung Cancer IHC. IHC staining of FFPE human lung cancer tissue was performed with NME6 Antibody at 2 ug/ml following heat-induced epitope retrieval in pH 8 EDTA buffer. HRP-conjugated secondary antibody and DAB were used for detection. NME6 staining is observed predominantly in the cytoplasm of tumor cells, with widespread staining across the cancer tissue. This NME6 Antibody demonstrates localization of Nucleoside Diphosphate Kinase 6 in human lung cancer tissue.

NME6 Antibody Human Spermatocytic Seminoma IHC. IHC staining of FFPE human spermatocytic seminoma testis tissue was performed with NME6 Antibody at 2 ug/ml following heat-induced epitope retrieval in pH 8 EDTA buffer. HRP-conjugated secondary antibody and DAB were used for detection. NME6 staining is observed predominantly in the cytoplasm of tumor cells, with widespread staining throughout the seminoma tissue. This NME6 Antibody demonstrates localization of Nucleoside Diphosphate Kinase 6 in human spermatocytic seminoma tissue.

NME6 Antibody Human Glioblastoma IHC. IHC staining of FFPE human glioblastoma tissue was performed with NME6 Antibody at 2 ug/ml following heat-induced epitope retrieval in pH 8 EDTA buffer. HRP-conjugated secondary antibody and DAB were used for detection. NME6 staining is observed predominantly in the cytoplasm of glioblastoma cells, with diffuse staining throughout the tumor tissue. This NME6 Antibody demonstrates localization of Nucleoside Diphosphate Kinase 6 in human glioblastoma tissue.